Observational studyBMC psychiatry2026
Antipsychotic dose is not associated with cognitive function in patients with schizophrenia aged under 40: a cross-sectional observational study with retrospective dose estimation.
Observational study in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to examine the relationship between antipsychotic dosage and cognitive performance in young patients with schizophrenia. A relatively homogeneous sample was selected to reduce clinical heterogeneity and improve sample comparability.
methodsIn this cross-sectional observational study, psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS), and cognitive performance was evaluated with the Montreal Cognitive Assessment (MoCA) in clinically stable patients with schizophrenia under the age of 40 who were followed at a Community Mental Health Center. Total antipsychotic dose was calculated using olanzapine equivalents, and 1-year cumulative exposure was estimated using the mg×day formula. Both frequentist and Bayesian analytical approaches were applied.
resultsNo significant correlations were found between either daily or cumulative antipsychotic doses and MoCA scores (r = 0.067; p = 0.675; BF₁₀ = 0.260; and r = 0.028; p = 0.864; BF₁₀ = 0.554, respectively). Longer illness duration and higher scores on all PANSS subscales were associated with lower MoCA scores, whereas longer education and older age at diagnosis were positively correlated with cognitive performance.
conclusionsAlthough prior research has suggested dose-related cognitive impairment, our findings did not provide evidence supporting this association in young, well-characterised patients within the constraints of a cross-sectional observational design. These results indicate that effective therapeutic dosing can be pursued with appropriate clinical monitoring, while acknowledging that potential cognitive effects should still be taken into consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.